Aditxt Inc (ADTX)

$0.13 -0.01 (-4.43%)
Market Cap 1.96M
Revenue (ttm) 650,000.00
Net Income (ttm) -32.38M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -4,981.54%
Debt to Equity Ratio 0.00
Volume 38,969,699
Avg Vol 16,594,119
Day's Range N/A - N/A
Shares Out 14.23M
Stochastic %K 11%
Beta 1.26
Analysts Strong Buy
Price Target $61.00

Latest News on ADTX

Aditxt's Board of Directors Unanimously Approve Positioning Pearsanta for IPO to Support Global Launch of its Early Cancer Detection Platform

Jan 13, 2025, 8:15 AM EST - 4 days ago

Aditxt's Board of Directors Unanimously Approve Positioning Pearsanta for IPO to Support Global Launch of its Early Cancer Detection Platform

Aditxt's Subsidiary Adimune Successfully Completes Preclinical Efficacy and Safety Studies for Its Immune Modulation Therapeutic ADI Platform, Advancing Toward First-in-Human Clinical Trials

Dec 12, 2024, 8:15 AM EST - 5 weeks ago

Aditxt's Subsidiary Adimune Successfully Completes Preclinical Efficacy and Safety Studies for Its Immune Modulation Therapeutic ADI Platform, Advancing Toward First-in-Human Clinical Trials

Evofem Biosciences Announces Financial Results for the Third Quarter of 2024

Nov 14, 2024, 4:36 PM EST - 2 months ago

Evofem Biosciences Announces Financial Results for the Third Quarter of 2024

Aditxt Provides Update on Equity Line of Credit, ATM Usage, and Outstanding Number of Shares

Nov 8, 2024, 8:30 AM EST - 2 months ago

Aditxt Provides Update on Equity Line of Credit, ATM Usage, and Outstanding Number of Shares

Aditxt's Target Acquisition Appili Therapeutics Announces Results of Special Meeting of Shareholders

Nov 7, 2024, 8:30 AM EST - 2 months ago

Aditxt's Target Acquisition Appili Therapeutics Announces Results of Special Meeting of Shareholders

Aditxt Acquisition Target Evofem Biosciences Secures Investor Support Through Voting Agreements for Merger with Aditxt's Subsidiary Adifem

Nov 6, 2024, 8:30 AM EST - 2 months ago

Aditxt Acquisition Target Evofem Biosciences Secures Investor Support Through Voting Agreements for Merger with Aditxt's Subsidiary Adifem

Evofem Secures Investor Support for Proposed Merger through Voting Agreements

Nov 6, 2024, 8:00 AM EST - 2 months ago

Evofem Secures Investor Support for Proposed Merger through Voting Agreements

Aditxt's Target Acquisition Appili Therapeutics Announces Alignment with FDA on Development Requirements for ATI-1801 Topical Antiparasitic Product NDA Submission

Oct 31, 2024, 8:30 AM EDT - 2 months ago

Aditxt's Target Acquisition Appili Therapeutics Announces Alignment with FDA on Development Requirements for ATI-1801 Topical Antiparasitic Product NDA Submission

Aditxt To Host Virtual Stakeholder Update and Q&A Session on Friday, November 1, 2024, at 11:30 AM Eastern Time

Oct 30, 2024, 5:00 PM EDT - 2 months ago

Aditxt To Host Virtual Stakeholder Update and Q&A Session on Friday, November 1, 2024, at 11:30 AM Eastern Time

Sylvia Hermina Joins Aditxt's Board of Directors, Elevating Leadership with Broader Perspectives

Oct 29, 2024, 8:15 AM EDT - 2 months ago

Sylvia Hermina Joins Aditxt's Board of Directors, Elevating Leadership with Broader Perspectives

Aditxt Completes Final Equity Investment and Key Milestone Under the Amended and Restated Merger Agreement with Evofem

Oct 28, 2024, 8:15 AM EDT - 2 months ago

Aditxt Completes Final Equity Investment and Key Milestone Under the Amended and Restated Merger Agreement with Evofem

Aditxt to Host a Virtual Fireside Chat with Aditxt CEO Amro Albanna and Evofem CEO Saundra Pelletier, Moderated by MD & Media Personality Dr. Drew Pinsky, on October 28, 2024, at 11:30 AM Eastern Time

Oct 21, 2024, 8:15 AM EDT - 3 months ago

Aditxt to Host a Virtual Fireside Chat with Aditxt CEO Amro Albanna and Evofem CEO Saundra Pelletier, Moderated by MD & Media Personality Dr. Drew Pinsky, on October 28, 2024, at 11:30 AM Eastern Time

Aditxt's Acquisition Target Appili Therapeutics Will Hold a Special Meeting of Shareholders on November 6, 2024, to Vote on the Transaction and Secure Appili's Shareholder Approval

Oct 10, 2024, 8:15 AM EDT - 3 months ago

Aditxt's Acquisition Target Appili Therapeutics Will Hold a Special Meeting of Shareholders on November 6, 2024, to Vote on the Transaction and Secure Appili's Shareholder Approval

Aditxt To Host Stakeholder Update and Q&A Session on Friday, October 11, 2024, at 11:30 AM Eastern Daylight Time

Oct 9, 2024, 10:52 AM EDT - 3 months ago

Aditxt To Host Stakeholder Update and Q&A Session on Friday, October 11, 2024, at 11:30 AM Eastern Daylight Time

Aditxt Completes Third Parent Equity Investment Under Amended and Restated Merger Agreement With Evofem

Oct 8, 2024, 8:15 AM EDT - 3 months ago

Aditxt Completes Third Parent Equity Investment Under Amended and Restated Merger Agreement With Evofem

Aditxt Delivers Shareholder Update and 2024 Year-End Plan

Oct 3, 2024, 8:15 AM EDT - 3 months ago

Aditxt Delivers Shareholder Update and 2024 Year-End Plan

Aditxt, Inc. (NASDAQ: ADTX) Announces 1-for-40 Reverse Stock Split Effective at the Open of Trading on October 2, 2024

Sep 27, 2024, 8:15 AM EDT - 4 months ago

Aditxt, Inc. (NASDAQ: ADTX) Announces 1-for-40 Reverse Stock Split Effective at the Open of Trading on October 2, 2024

Evofem Biosciences Files Preliminary Proxy for Stockholder Approval of the Acquisition by Aditxt

Sep 24, 2024, 8:15 AM EDT - 4 months ago

Evofem Biosciences Files Preliminary Proxy for Stockholder Approval of the Acquisition by Aditxt

Aditxt's Subsidiary Pearsanta to Collaborate with Evofem Biosciences for Targeted U.S. Launch of Endometriosis Diagnostic in Mid-2025

Sep 20, 2024, 8:15 AM EDT - 4 months ago

Aditxt's Subsidiary Pearsanta to Collaborate with Evofem Biosciences for Targeted U.S. Launch of Endometriosis Diagnostic in Mid-2025

Aditxt and Evofem Sign Second Amendment to Amended and Restated Merger Agreement, Target Closing of Acquisition in Fourth Quarter of 2024

Sep 9, 2024, 8:15 AM EDT - 4 months ago

Aditxt and Evofem Sign Second Amendment to Amended and Restated Merger Agreement, Target Closing of Acquisition in Fourth Quarter of 2024

Aditxt Subsidiary Pearsanta Submits a Grant Application Seeking to Advance Clinical Trials for Mitomic® Prostate Test, Targeting Early Detection in High-Risk Patients

Sep 4, 2024, 8:15 AM EDT - 4 months ago

Aditxt Subsidiary Pearsanta Submits a Grant Application Seeking to Advance Clinical Trials for Mitomic® Prostate Test, Targeting Early Detection in High-Risk Patients

Aditxt to Present at the H.C. Wainwright 26th Annual Global Investment Conference September 9th-11th, 2024

Aug 29, 2024, 8:15 AM EDT - 5 months ago

Aditxt to Present at the H.C. Wainwright 26th Annual Global Investment Conference September 9th-11th, 2024

Aditxt's Precision Health Subsidiary, Pearsanta, Appoints Christopher Mitton as President as it Seeks to Complete Clinical Validation Studies for its Mitomic® Endometriosis Test (MET™) and Mitomic® Prostate Test (MPT™)

Aug 26, 2024, 8:15 AM EDT - 5 months ago

Aditxt's Precision Health Subsidiary, Pearsanta, Appoints Christopher Mitton as President as it Seeks to Complete Clinical Validation Studies for its Mitomic® Endometriosis Test (MET™) and Mitomic® Prostate Test (MPT™)

Aditxt Announces Third Amendment to Arrangement Agreement with Appili Therapeutics

Aug 21, 2024, 8:15 AM EDT - 5 months ago

Aditxt Announces Third Amendment to Arrangement Agreement with Appili Therapeutics

Evofem Biosciences Addresses the Impact of GLP-1 Medications on Oral Contraceptive Absorption and Introduces Phexxi as a Non-Oral Solution

Aug 20, 2024, 8:17 AM EDT - 5 months ago

Evofem Biosciences Addresses the Impact of GLP-1 Medications on Oral Contraceptive Absorption and Introduces Phexxi as a Non-Oral Solution

Evofem Biosciences Announces Financial Results for the Second Quarter of 2024

Aug 14, 2024, 7:00 AM EDT - 5 months ago

Evofem Biosciences Announces Financial Results for the Second Quarter of 2024

Aditxt Announces the Successful Passage of all Proposals at Recent Annual Shareholders' Meeting, Setting the Stage for 2024 and 2025 Strategic Plans

Aug 13, 2024, 8:15 AM EDT - 5 months ago

Aditxt Announces the Successful Passage of all Proposals at Recent Annual Shareholders' Meeting, Setting the Stage for 2024 and 2025 Strategic Plans

Aditxt Announces Closing of $1.2 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules

Aug 9, 2024, 4:15 PM EDT - 5 months ago

Aditxt Announces Closing of $1.2 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules

Aditxt Announces $1.2 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules

Aug 9, 2024, 8:00 AM EDT - 5 months ago

Aditxt Announces $1.2 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules

Aditxt Subsidiary Pearsanta Seeks Clinical Trial Translational Endpoints Research Award for Early Detection of Ovarian Cancer

Aug 7, 2024, 8:15 AM EDT - 5 months ago

Aditxt Subsidiary Pearsanta Seeks Clinical Trial Translational Endpoints Research Award for Early Detection of Ovarian Cancer

Evofem Biosciences to Present at the OTCQB Venture Virtual Investor Conference on August 1st

Jul 25, 2024, 9:00 AM EDT - 6 months ago

Evofem Biosciences to Present at the OTCQB Venture Virtual Investor Conference on August 1st

Aditxt Signs Second Amendment to the Arrangement Agreement with Appili Therapeutics, Targeting September 30 Closing of the Acquisition

Jul 25, 2024, 8:30 AM EDT - 6 months ago

Aditxt Signs Second Amendment to the Arrangement Agreement with Appili Therapeutics, Targeting September 30 Closing of the Acquisition

Evofem Signs Phexxi® License Agreement for Middle East with Pharma 1

Jul 23, 2024, 8:47 AM EDT - 6 months ago

Evofem Signs Phexxi® License Agreement for Middle East with Pharma 1

Aditxt and Evofem Amend and Restate Merger Agreement, Targeting September 30 Closing

Jul 17, 2024, 6:30 AM EDT - 6 months ago

Aditxt and Evofem Amend and Restate Merger Agreement, Targeting September 30 Closing

Lupin Divests U.S. Commercial Women's Health Specialty Business to Evofem, including SOLOSEC

Jul 15, 2024, 7:20 AM EDT - 6 months ago

Lupin Divests U.S. Commercial Women's Health Specialty Business to Evofem, including SOLOSEC

Hello Alpha Partners with Evofem to Offer Phexxi® as a Hormone-Free Contraception Solution on its Platform for Women's Healthcare

Jun 27, 2024, 8:36 AM EDT - 7 months ago

Hello Alpha Partners with Evofem to Offer Phexxi® as a Hormone-Free Contraception Solution on its Platform for Women's Healthcare

Evofem Announces Issuance of New U.S. Patent Covering Phexxi Composition of Matter

Jun 11, 2024, 8:36 AM EDT - 7 months ago

Evofem Announces Issuance of New U.S. Patent Covering Phexxi Composition of Matter

Evofem Biosciences Announces Financial Results for the First Quarter of 2024

May 15, 2024, 6:50 AM EDT - 8 months ago

Evofem Biosciences Announces Financial Results for the First Quarter of 2024

CORRECTING and REPLACING Aditxt Announces Pricing of $4.2 Million Private Placement Priced At-The-Market under Nasdaq Rules

May 3, 2024, 2:14 PM EDT - 9 months ago

CORRECTING and REPLACING Aditxt Announces Pricing of $4.2 Million Private Placement Priced At-The-Market under Nasdaq Rules

Aditxt Announces Pricing of $4.2 Million Private Placement Priced At-The-Market under Nasdaq Rules

May 3, 2024, 9:00 AM EDT - 9 months ago

Aditxt Announces Pricing of $4.2 Million Private Placement Priced At-The-Market under Nasdaq Rules

Aditxt Signs a Definitive Agreement to Acquire Appili Therapeutics Inc., Developer of a Biodefense Vaccine Funded by the U.S. Department of Defense (DoD)

Apr 2, 2024, 8:30 AM EDT - 10 months ago

Aditxt Signs a Definitive Agreement to Acquire Appili Therapeutics Inc., Developer of a Biodefense Vaccine Funded by the U.S. Department of Defense (DoD)

Evofem Reports $18.2 million of Phexxi Net Product Sales in 2023

Mar 27, 2024, 8:36 AM EDT - 10 months ago

Evofem Reports $18.2 million of Phexxi Net Product Sales in 2023

Evofem Negotiates Improved Rebate for Hormone-Free "In the Moment" Contraceptive PHEXXI with Medi-Cal

Mar 20, 2024, 8:54 AM EDT - 10 months ago

Evofem Negotiates Improved Rebate for Hormone-Free "In the Moment" Contraceptive PHEXXI with Medi-Cal

For Women Using GLP-1 Receptor Agonists who take Oral Birth Control Pills, Hormone-Free Phexxi Contraceptive Gel is a Logical Solution to Help Prevent Unintended Pregnancy

Mar 7, 2024, 7:54 AM EST - 11 months ago

For Women Using GLP-1 Receptor Agonists who take Oral Birth Control Pills, Hormone-Free Phexxi Contraceptive Gel is a Logical Solution to Help Prevent Unintended Pregnancy

Evofem Biosciences Announces Strong Preliminary Results, Record Phexxi Net Sales for Fiscal 2023

Feb 1, 2024, 8:00 AM EST - 1 year ago

Evofem Biosciences Announces Strong Preliminary Results, Record Phexxi Net Sales for Fiscal 2023

Aditxt, Inc. Acquires Proprietary Electroencephalography (EEG) Brain Monitoring Technologies and Devices, Including NeuroCap™ and NeuroEEG™ for Telehealth and Tele-neurology Applications

Jan 30, 2024, 8:30 AM EST - 1 year ago

Aditxt, Inc. Acquires Proprietary Electroencephalography (EEG) Brain Monitoring Technologies and Devices, Including NeuroCap™ and NeuroEEG™ for Telehealth and Tele-neurology Applications

Aditxt, Inc.'s Subsidiary Pearsanta, Inc. Acquires MDNA Life Sciences Inc.'s Proprietary Mitomic™ Testing Platform Pioneering Early Disease and Cancer Detection in a Transaction Valued at Approximately $25 Million

Jan 8, 2024, 8:30 AM EST - 1 year ago

Aditxt, Inc.'s Subsidiary Pearsanta, Inc. Acquires MDNA Life Sciences Inc.'s Proprietary Mitomic™ Testing Platform Pioneering Early Disease and Cancer Detection in a Transaction Valued at Approximately $25 Million

Aditxt Announces Closing of $6.0 Million Private Placement Priced At-The-Market under Nasdaq Rules

Jan 5, 2024, 8:30 AM EST - 1 year ago

Aditxt Announces Closing of $6.0 Million Private Placement Priced At-The-Market under Nasdaq Rules

Aditxt, Inc. Regains Compliance with Nasdaq Stockholders' Equity Requirement

Jan 2, 2024, 8:30 AM EST - 1 year ago

Aditxt, Inc. Regains Compliance with Nasdaq Stockholders' Equity Requirement

Aditxt Announces $6 Million Private Placement Priced At-The-Market under Nasdaq Rules

Dec 29, 2023, 5:07 PM EST - 1 year ago

Aditxt Announces $6 Million Private Placement Priced At-The-Market under Nasdaq Rules